medigraphic.com
ISSN 0188-9796 (Print)

2005, Number s1

<< Back Next >>

Rev Endocrinol Nutr 2005; 13 (s1)

Can we achieve the goal of normoglycemia in type 2 diabetes?

Cooppan R

Language: English
References: 10
Page: 22-25
PDF size: 63.64 Kb.


Text Extraction

Blood glucose levels are regulated very tightly in the non diabetic individual. This is the result of a dynamic interaction between glucose absorption, insulin secretion and insulin action. It has now become clear from studies such as the DCCT, Kummamoto and UKPDS that tight glycemic control in patients with diabetes, not only prevents microvascular complications, but also slows the progression. More recently the EDIC trial in type 1 diabetes demonstrated the benefits of early tight glycemic control in slowing the development of micro and macrovascular disease even if control deteriorates later. One of the major messages of the UKPDS was that oral monotherapies fail with time and that combination treatments using two and even three oral drugs will be necessary. It is therefore important to try and treat diabetes with the goal of normalizing the blood sugar values provided the well being and safety of the patient is not threatened. One of the limiting factors in achieving and maintaining normoglycemia, especially in type 1 diabetes and also in type 2 diabetes has been the issue of iatrogenic hypoglycemia.


REFERENCES

  1. Standards of medical care in diabetes. Diabetes Care 2005; 28 Suppl 1: S4-36.

  2. Inzucchi S. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002; 287: 360-372.

  3. Defronzo RA. Pharmacolgical therapy for type 2 diabetes mellitus. Annals Intern Med 1999; 131(40: 281-303.

  4. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. New Eng J Med 2002; 347: 1342-1349.

  5. Riddle MC, Scheinder. Beginning Insulin treatment of Obese Patients with Evening 70/30 Insulin Plus Glimepiride Versus Insulin alone. Diabetes Care 1998; 21(7): 1052-1057.

  6. Rosenstock J, Schwartz SL, Clark CM et al. Basal Insulin Therapy in Type 2 Diabetes. Diabetes Care 2001; 24(4): 631-636.

  7. Yki-Jarvinen H, Ryysy L, Nikkila K et al. Comparison of bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus. Annals Intern Med 1999; 130(5): 389-396.

  8. Kendall DM, Riddle MC, Rosenstock J et al. Effects of Exenatide (Exendin-4) on Glycemic Control over 30 weeks in Patients With Type 2 Diabetes treated with Metformin and a Sulfonylurea. Diabetes Care 2005; 28: 1083-1091.

  9. Defronzo RA, Ratner RE, Han J et al. Effects of Exenatide (Exendin-4) on Glycemic control and Weight over 30 weeks in Metformin – Treated patients with Type 2 Diabetes. Diabetes Care 2005; 28: 1092-1100.

  10. Hollander PA, Levy P, Fineman MS et al. Pramlintide a s an adjunct to insulin therapy improves long term glycemic and weight control in patients with type 2 diabetes mellitus: a one year randomized controlled clinical trial. Diabetes Care 26: 784-790,2003




2020     |     www.medigraphic.com